Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants.
Pompe disease
newborn screening
Journal
International journal of neonatal screening
ISSN: 2409-515X
Titre abrégé: Int J Neonatal Screen
Pays: Switzerland
ID NLM: 101665400
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
11
12
2019
accepted:
18
01
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
Statewide newborn screening for Pompe disease began in Illinois in 2015. As of 30 September 2019, a total of 684,290 infants had been screened and 395 infants (0.06%) were screen positive. A total of 29 cases of Pompe disease were identified (3 infantile, 26 late-onset). While many of the remainder were found to have normal alpha-glucosidase activity on the follow-up testing (234 of 395), other findings included 62 carriers, 39 infants with pseudodeficiency, and eight infants who could not be given a definitive diagnosis due to inconclusive follow-up testing.
Identifiants
pubmed: 33073003
doi: 10.3390/ijns6010004
pii: ijns6010004
pmc: PMC7422983
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
4Informations de copyright
© 2020 by the authors.
Déclaration de conflit d'intérêts
Conflicts of InterestB.K.B. has received consulting fees and/or honoraria from Sanofi Genzyme, Biomarin, Shire (a Takeda company), Ultragenyx, Moderna, Horizon, Alexion, Chiesi, Denali, JCR Pharma, Aeglea, and Agios. She has conducted contracted research for Sanofi Genzyme, Biomarin, Shire, Alexion, Ultragenyx, and Sangamo and Homology Medicines. J.C. has also received grant support for research from: Sanofi Genzyme, Shire, Amicus, BioMarin, and Protalix. Dorothy K. Grange conducts contracted research for Biomarin and Shire (a Takeda company). The following authors declare no conflict of interest: K.B., S.R.B., K.M.C., J.F., D.G., R.H., L.H., G.E.H., H.S., R.S., and P.S.
Références
J Pediatr. 2015 Jan;166(1):172-7
pubmed: 25444528
J Pediatr. 2016 Feb;169:174-80.e1
pubmed: 26685070
Pediatrics. 2008 Jul;122(1):e39-45
pubmed: 18519449
Genet Med. 2006 May;8(5):267-88
pubmed: 16702877
JAMA Pediatr. 2018 Jul 1;172(7):696-697
pubmed: 29813145
Genet Med. 2019 Apr;21(4):887-895
pubmed: 30214072
Hum Mutat. 2019 Nov;40(11):2146-2164
pubmed: 31342611
Pediatrics. 2009 Dec;124(6):e1116-25
pubmed: 19948615
Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):50-8
pubmed: 22252961
J Pediatr. 2018 Jul;198:308-312
pubmed: 29627187
Mol Genet Metab. 2009 Jul;97(3):190-5
pubmed: 19362502
Pediatr Res. 2009 Sep;66(3):329-35
pubmed: 19542901
J Pediatr. 2017 Nov;190:130-135
pubmed: 28728811
Mol Genet Metab. 2010 Jan;99(1):26-33
pubmed: 19775921
Genet Med. 2012 Jan;14(1):135-42
pubmed: 22237443
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814660
N Engl J Med. 2010 Apr 15;362(15):1396-406
pubmed: 20393176
JIMD Rep. 2015;19:67-73
pubmed: 25681082